Neurology Medical News about multiple sclerosis;T2 magnetic resonance imaging

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
Multiple Sclerosis, 07/06/09

Bonzano L et al. – Defining either active T2 or gadolinium (Gd)-enhancing lesions as a magnetic resonance imaging (MRI) endpoint is not key to monitoring MRI activity in multiple sclerosis (MS) clinical trials. The choice of the best MRI endpoint should be based on other considerations (sensitivity, reproducibility, time for assessment, safety, pt comfort). Further monitoring active T2 lesions could allow less expensive trials, without requiring injection of Gd-based contrast agents.

Methods

Study of the relationship between treatment effects estimated on T2-weighted or Gd-enhanced T1-weighted MRI
Data extraction from published randomized clinical trials in relapsing-remitting MS with frequent MRI, reporting both active T2 and Gd-enhancing lesions
Regression analysis between treatment effects estimated on 2 different MRI endpoints

Results